仲佳,2015年毕业于北京大学医学部,肿瘤学博士,副主任医师,北京市医学奖励基金会肺癌青年专业委员会秘书,中国老年肿瘤学会委员。致力于肺癌精准治疗及转化性研究。发表SCI论文数篇,曾多次在中国临床肿瘤学大会(CSCO)及世界肺癌大会(WCLC)等大会发言。
社会任职
北京市医学奖励基金会肺癌青年专家委员会秘书
中国老年学会老年肿瘤专业委员会委员
北京抗癌协会肺癌专业委员会委员
获奖荣誉
csco 35 under 35优秀选手
医师报第七届医学家年会“十大医学新锐”
科研成果
1. Yang X#, Zhong J#, Yu Z#, Zhuo M, Zhang M, Chen R, Xia X, Zhao J. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. BMC Cancer. 2021 Oct 15;21(1):1107. (IF 4.430)#共同第一作者
2. Wang L, Zhao J, An T, Wang Y, Zhuo M, Wu M, Wang Z, Li J, Yang X, Chen H, Zhong J*. Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. Front Oncol. 2020 Jul 16;10:1137. (IF 6.244)*通讯作者
3. Zhong J, Zheng QW, Zhao J, Wang ZP, Wu MN, Zhuo ML, Wang YY, Li JJ, Yang X, Chen HX, An TT. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2020 Sep 23;42(9):771-776.
4. Zhong J, Guo Z, Fan L, Zhao X, Zhao B, Cao Z, Cheng L, Shi Y, Li X, Zhang Y, An T, Wu M, Wang Y, Zhuo M, Li J, Yang X, Chen H, Jia B, Zhao J. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. Thorac Cancer. 2019 Nov;10(11):2088-2095.(IF 3.500)
5. Zhong J, Zheng Q, An T, Zhao J, Wu M, Wang Y, Zhuo M, Li J, Zhao X, Yang X, Jia B, Chen H, Dong Z, Wang J, Chi Y, Zhai X, Wang Z. Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. Thorac Cancer. 2019 Sep;10(9):1788-1797. (IF 3.500)
6. Zhong J, Zheng Q, Gao E, Dong Z, Zhao J, An T, Wu M, Zhuo M, Wang Y, Li J, Wang S, Yang X, Chen H, Jia B, Wang J, Wang Z.Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma.Thorac Cancer. 2018 Feb;9(2):291-297.(IF 3.500)
7. Zhong J, Li L, Wang Z, Bai H, Gai F, Duan J, Zhao J, Zhuo M, Wang Y, Wang S, Zang W, Wu M, An T, Rao G, Zhu G, Wang J.Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).J Thorac Oncol. 2017 Dec;12(12):1766-1778.
医师资格证
在线问诊
手术后靶向治疗,恢复很好!非常感谢仲主任,耐心的讲解病情,及...
病情描述:靶向药治疗复查 看病过程:仲佳主任提前开具血液化验...
病情描述:肺癌晚期 看病过程:面诊,在线解答。我们是外地慕名...